News
First U.S. Patient Randomized in a Phase 3 Trial for Osteoarthritis of the Knee
New Orleans, LA – A big congratulations to Dr. Patrick Dennis and his outstanding site team for randomizing the first U.S. patient in a Phase 3 trial for osteoarthritis of the knee! We’re proud to recognize this major milestone with Dr. Dennis, who continues to lead with excellence and dedication in every study. As a long-time research partner with DelRicht Research, conducting over 100 trials, Dr. Dennis has shown time and again what it means...
FDA Approves Atzumi for Acute Treatment of Migraine
We’re thrilled to congratulate Satsuma Pharmaceuticals, Inc. on receiving U.S. FDA approval for Atzumi™ (dihydroergotamine) nasal powder for the acute treatment of migraine in adults—a significant milestone for the millions impacted by migraines nationwide. At DelRicht Research, we are incredibly proud of our principal investigators and teams, who played a vital role in the research that led to this approval, serving as trusted clinical trial partners across six U.S. site locations. Their expertise and dedication...
Exceeded Target Enrollment by 200% for a US-Based Phase 3 Gout Trial
Atlanta, GA – We’re celebrating a significant milestone at Springer Wellness & Restorative Health, where Robert Springer, MD, one of our principal investigators, has successfully wrapped enrollment for a Phase 3 gout study — and delivered truly impressive results: – Exceeded target enrollment expectations by over 200% – Screened the first patient on the same day the site was activated – Led diversity enrollment with 78% of enrolled participants representing diverse populations Dr. Springer has...
